Azetukalner vs Opakalim

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Epilepsy

Shared mechanism: Kv7 potassium channel · full Epilepsy pipeline

Azetukalner

Developed by Xenon Pharmaceuticals

Phase 3 in Epilepsysmall molecule
Reliable signal

NCT05614063 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled Phase 3 trial in 380 adults with focal epilepsy. Both azetukalner doses produced a significantly greater reduction in monthly seizure frequency than placebo, 25 mg: -53.2% vs -10.4%; 15 mg: -34.5% vs -10.4%, meeting the trial primary comparison.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: April 2027 · NCT05667142 (registry estimate)

Reported efficacy

Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo. (From baseline through to the double blind period (week 12)): Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4% (met)

Result source: NCT05614063

Opakalim

Developed by Biohaven and partners

Phase 2/3 in Epilepsysmall molecule
Weak signal

NCT06425159 · Phase 2/3 · terminated

This randomized, quadruple-masked Phase 2/3 study in idiopathic generalized epilepsy was terminated early by the sponsor after enrolling 27 participants. The company reports a longer time to second seizure with opakalim but no formal statistical test, so the result is unclear; a study stopped this far short of its plan is weak evidence.

Next expected readout: December 2026 · NCT06443463 (registry estimate)

Reported efficacy

Time to the Second Day with a Generalized Tonic Clonic (GTC) Seizure During the 24- week Double-blind Treatment Period (Baseline to Week 24 of Double-Blind Treatment Period): Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26). (unclear)

Result source: NCT06425159

Results for Epilepsy

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAzetukalnerOpakalim
Seizure frequency, % change—Not posted · NCT05614063—Trial running · NCT06309966
50% responder rate—Not posted · NCT05614063—Trial running · NCT06309966
Seizure freedom—Not posted · NCT05614063—Trial running · NCT06309966

Seizure frequency, % change

Azetukalner
—Not posted · NCT05614063
Opakalim
—Trial running · NCT06309966

50% responder rate

Azetukalner
—Not posted · NCT05614063
Opakalim
—Trial running · NCT06309966

Seizure freedom

Azetukalner
—Not posted · NCT05614063
Opakalim
—Trial running · NCT06309966
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Azetukalner
Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4% NCT05614063 · Phase 3 · design grade: strong · publication or press release
Opakalim
Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26). NCT06425159 · Phase 2/3 · design grade: weak · reviewed ClinicalTrials.gov result

Focal Onset Seizures

Shared mechanism: Kv7 potassium channel · full Focal Onset Seizures pipeline

Azetukalner

Developed by Xenon Pharmaceuticals

Phase 3 in Focal Onset Seizuressmall molecule
Reliable signal

NCT05614063 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled Phase 3 trial in 380 adults with focal epilepsy. Both azetukalner doses produced a significantly greater reduction in monthly seizure frequency than placebo, 25 mg: -53.2% vs -10.4%; 15 mg: -34.5% vs -10.4%, meeting the trial primary comparison.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: January 2028 · NCT05716100 (registry estimate)

Reported efficacy

Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo. (From baseline through to the double blind period (week 12)): Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4% (met)

Result source: NCT05614063

Opakalim

Developed by Biohaven and partners

Phase 2/3 in Focal Onset Seizuressmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT06443463 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Focal Onset Seizures

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Opakalim: no structured comparison results are available for Focal Onset Seizures.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Azetukalner
Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4% NCT05614063 · Phase 3 · design grade: strong · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Azetukalner's landscape · Opakalim's landscape